Results of a consensus meeting of clinical experts investigating sphingotec’s diagnostic solutions for acute and critical care in COVID-19. sphingotec’s biomarkers penKid, bio-ADM, and DPP3 previously shown to predict the need for organ support in numerous critical care conditions also have utility in risk stratification of severely ill COVID-19 patients. Hennigsdorf/Berlin, Germany, June 18, 2020…Read more
Recent Posts by ruxandralenz
DPP3 is a highly dynamic marker for predicting and monitoring cardiac depression in burn patients High DPP3 blood concentrations are indicating multiple organ failure and poor outcomes sphingotec commercializes a rapid CE-IVD test for DPP3 on its proprietary point-of-care platform Nexus IB10 Hennigsdorf/Berlin, Germany, May 14, 2020 – Diagnostics company SphingoTec GmbH (“sphingotec”) and…Read more
Hennigsdorf/Berlin, Germany, April 16, 2020 - Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that it has appointed Dr. Achim Plum as Managing Director and Chief Commercial Officer (CCO) of the company. As CCO, Dr. Plum will focus on driving the global commercialization of sphingotec’s IVD solutions for novel biomarkers for acute and critical…Read more
New study data show that monitoring blood levels of sphingotec’s endothelial function biomarker bio-ADM® on top of guideline parameter lactate improves risk stratification of sepsis patients admitted to intensive care units Monitoring of both, lactate and bio-ADM®, in sepsis patients allows early identification of patients that require immediate intervention at admission to the ICU. Sphingotec…Read more
Recent Comments by ruxandralenz
No comments by ruxandralenz yet.